Phase 2 N=32 SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
Familial Amyotrophic Lateral Sclerosis
Primary: Mean Change in SOD1 CSF — 6.8 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 3; 3 Participants
Phase 3 N=139 Long-Term Evaluation of BIIB067 (Tofersen)
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs) — 31; 63; 43; 16 Participants
Phase 2 N=22 A Trial of Tocilizumab in ALS Subjects
ALS · Amyotrophic Lateral Sclerosis · Lou Gehrig's Disease
Primary: Number of Patients Tolerant to Study Drug — 6; 12 Participants — p=0.602
Phase 2 N=15 A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
ALS
Primary: ALS Functional Rating Scale-revised Version (ALSFRS-R) Slope — -0.39; -0.57 points per month — p=0.32
Phase 2 N=80 Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: ALS Functional Rating Scale-Revised (ALSFRS-R) — -1.00; -1.26 score on a scale
Phase 2 N=31 Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With an Average Increase in ALSFRS-R Score of One Point Per Month — 0 Participants
Phase 2 N=36 Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) — -1.20; -0.94 units on a scale — p=0.07
Phase 2 N=16 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants Who Had Any Serious Adverse Events or Any Adverse Events With Severity Higher Than "Moderate". — 0; 0 Participants
Phase 2 N=54 Multiple Doses of AT-1501-A201 in Adults With ALS
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability — 8; 8; 10; 16 participants
Phase 3 N=330 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
Amyotrophic Lateral Sclerosis
Primary: Rate of Change in Composite Manual Muscle Testing (MMT) Score — 0.44; 0.39 MMT units per month — p=0.529
Phase 2 N=13 Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) — -1.0; -1.5; -4.0; -5.5 units on a scale — p=<0.0001
Phase 2 N=366 Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Slope of Change From Baseline in the ALS Functional Rating Scale (ALSFRS-R) — -1.05; -1.00 Units on a Scale per Month — p=0.4807
Phase 2 N=45 Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Electromyography Measures of Disease Progression. — -39.6; -31.8 percent change — p=0.4304
Phase 2 N=303 Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Joint Rank Scores for Combined Analysis of Function (Amyotrophic Lateral Sclerosis Functional Rating Scale Revised [ALSFRS-R] Score) and 48 Week Overall Survival — 15.0…
Phase 3 N=239 Arimoclomol in Amyotropic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Combined Assessment of Function and Survival (CAFS) — 0.51; 0.49 score on a scale — p=0.6208
Phase 2 N=147 The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis
Primary: Pharmacodynamic Biomarkers: MCP-1 On-treatment Period Variation — 4.6; 2.2 pg/ml — p=0.6346
Phase 2 N=70 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALS — 17; 34; 8; 11 Participants
Phase 2 N=12 Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score — 39.8; -1.3; -2.5; -5.0 units on scale
Phase 2 N=358 A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Change in Monthly Rate of Decline in ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Score - Revised) — 1.20; 1.01 points per month
N/A N=14 Remotely Supervised tDCS for Slowing ALS Disease Progression
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change in Revised ALS Functioning Rating Scale (ALSFRS-R) — -1; -7.1; -3.2; -7.1 Change score on ALSFRS-R
N/A N=34 DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS
Amyotrophic Lateral Sclerosis
Primary: Change in Percent of Expected Lung Force Vital Capacity — -1.25 % Expected Forced Vital Capacity
N/A N=30 Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Change in Muscle Strength From Baseline — 74.7; 74.7; 76.4; 74.5 units on a scale — p==0.001
Phase 1 N=118 HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Percent Change in HERV-K Level — -30.7 Percent change
Phase 3 N=25 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -6.52; -6 units on a scale
Phase 2 N=137 AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis · Motor Neuron Disease · Neuromuscular Diseases
Primary: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change — -1.66; -1.24 Change in ALSFRS-R Total Score Per Month — p=0.03
Phase 3 N=206 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.7; -6.35 units on a scale
Phase 2 N=89 Therapy in Amyotrophic Lateral Sclerosis (TAME)
Amyotrophic Lateral Sclerosis · Frontal Temporal Dementia
Primary: The Primary Comparison for Efficacy Will be Based on a Linear Mixed Effects (LME) Model Fit to the ALSFRS-R Data for the Patients Followed Over 36 Weeks. — -0.290…
Phase 2 N=60 ALS Reversals - Lunasin Regimen
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99
Phase 3 N=181 Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.5; -4.2; -5.4 units on a scale